Martina Baldin

Dr. Martina Baldin

orcid
PhD student, ECVCP resident

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in Frontiers in Veterinary Science
Verified
Journal Article
Open access
MCMarco Graziano Castaman
Marco Graziano Castaman
MOMargherita Orlandi
Margherita Orlandi
MBMartina Baldin
Martina Baldin
MMMaria Massaro
Maria Massaro
MRMattia Ridolfi
Mattia Ridolfi
MZMaristella Zambelli
Maristella Zambelli
A 10-month-old female domestic meerkat ( Suricata suricatta ) was presented with a cutaneous nodule in the left axillary region. The animal was clinically healthy and radiographs showed no evidence of involvement of visceral organs. Based on fine-needle aspirate that revealed numerous well-differentiated mast cells, a mast cell tumor was suspected. Surgical excision was performed and the mass submitted for histologic examination. Histopathological findings showed a round cell tumor, with marked cellular atypia and moderate mitotic activity; Giemsa special staining revealed a large number of fine cytoplasmic metachromatic granules. Histological and histochemical findings confirmed the cytological suspicion of a mast cell tumor. Based on prognostic factors used in the canine species, immunohistochemistry with antibodies against Ki67 (a marker of cellular proliferation) and CD117 (a KIT receptor localization marker) revealed that 90% of the neoplastic population was positive for CD117 (with a membranous staining pattern), and the Ki67 index was 28. The patient did not show local recurrence and sign of distant metastases at the 10 months follow-up. Based on literature search no previous reports of mast cell tumour in meerkats were retrieved. Therefore, this case highlights a previously undocumented presentation of mast cell tumor in this species, contributing to the expanding knowledge of neoplastic conditions in exotic companion animals.

1 June 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
MBMartina Baldin
Martina Baldin
Maria Elena GelainMaria Elena Gelain
Maria Elena Gelain
GMGiacomo Marolato
Giacomo Marolato
SBSilvia Bedin
Silvia Bedin
MBMichele Berlanda
Michele Berlanda
FBFederico Bonsembiante
Federico Bonsembiante
Acute phase proteins (APPs) are part of the innate immune response, changing during inflammation. An Acute Phase Index (API) is a calculated value that combines multiple APPs. In human medicine, the introduction of APIs has improved outcome monitoring. In veterinary medicine, APIs have been evaluated in livestock and dogs with Leishmaniasis. This study aimed to calculate an API and evaluate its significance in cancer-bearing dogs. Sera were collected from 55 dogs, which were classified by neoplastic category and survival times (> or < than 30 and 90 days). For 32 dogs, multiple samples were available. The API included C-Reactive Protein (CRP) and haptoglobin as positive APPs, and albumin and Paraoxonase-1 (PON-1) as negative APPs. An alternative API excluding PON-1 was calculated. PON-1 levels were lower in round-cell tumors, suggesting increased oxidative stress. Moreover, API increased and PON-1 activity decreased in the last sample in dogs that died before the end of the study. Dogs with shorter survival times showed increased APIs and CRP levels. APIs with and without PON-1 greater than 0.049 and 0.202 at the first sampling were associated with a 3.7- and 4.4-fold higher probability of death, respectively. These results suggest a potential prognostic value of API in dogs with neoplasia.

4 September 2026 in Journal of Veterinary Diagnostic Investigation
Verified
Journal Article
Closed access
MBMartina Baldin
Martina Baldin
SFSabrina Fasoli
Sabrina Fasoli
KVKateryna Vasylyeva
Kateryna Vasylyeva
CAChiara Agnoli
Chiara Agnoli
MFMaria Giulia Ferrari
Maria Giulia Ferrari
FDFrancesco Dondi
Francesco Dondi
The BC-75R Vet (Mindray Animal Medical) is a multi-species hematology analyzer that uses electrical impedance and SF-Cube technology (combining laser scatter, fluorescence, and 3-dimensional analysis) for CBC and reticulocyte analysis. We evaluated its analytical performance and compared it with the Advia 2120i (Siemens), a widely used analyzer in veterinary clinical pathology. CBCs were performed on EDTA-anticoagulated blood samples from 411 dogs and 225 cats submitted for routine testing. Analytical precision, linearity, carryover, and total observed error (TE obs ) were assessed according to ASVCP guidelines. We used a 2120i as the reference method and manual differential counts for WBC evaluation. RIs were calculated from 131 healthy dogs and 53 cats. The BC-75R Vet fulfilled the ASVCP requirements for repeatability (CVs < 5% for most variables) and linearity ( r > 0.97), with negligible carryover. TE obs values were within ASVCP allowable error limits, except for WBC types in QC material, which remained acceptable for in-clinic use. Agreement with the 2120i was acceptable for most RBC-related variables; however, systematic and proportional errors were found for mean corpuscular hemoglobin concentration (MCHC) in both species, and a systematic error for mean corpuscular volume (MCV) was found in dogs. Agreement for WBC and platelet counts was generally good, although discrepancies were noted for monocyte and mean platelet volume in both species. These differences likely reflect methodologic differences and known challenges in feline hematology. Despite these limitations, the BC-75R Vet met ASVCP standards and appears suitable for routine testing in dogs and cats. Manual smear review remains essential in selected cases.